Targeting TNF-α has emerged as a cornerstone in managing RA, with biological therapies such as adalimumab, a fully human monoclonal antibody that binds to TNF-α, inhibiting its pro-inflammatory effects [4]. Here, TNF is linked to rheumatoid arthritis.